Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $46
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $40 to $46.
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $40 to $46.